# Novel Innate Immune Adjuvant for Avian Influenza. West Nile Virus, and ZIKA Vaccines

> **NIH NIH N01** · UNIVERSITY OF WASHINGTON · 2021 · $144

## Abstract

The NIAID/DAIT Adjuvant Development Program supports the development of new candidate vaccine adjuvants through immunological characterization studies and lead compound optimization, up to and including IND-enabling studies, all towards licensure for human use. Adjuvants will be studied with currently licensed or new investigational vaccines to protect against infection by NIAID emerging and re-emerging infectious disease pathogens.

## Key facts

- **NIH application ID:** 10413776
- **Project number:** 272201300023C-P00012-9999-1
- **Recipient organization:** UNIVERSITY OF WASHINGTON
- **Principal Investigator:** MICHAEL GALE
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $144
- **Award type:** —
- **Project period:** 2013-09-30 → 2021-09-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10413776

## Citation

> US National Institutes of Health, RePORTER application 10413776, Novel Innate Immune Adjuvant for Avian Influenza. West Nile Virus, and ZIKA Vaccines (272201300023C-P00012-9999-1). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10413776. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*